Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
WHO grants prequalification to Cervarix®: GSK’s vaccine to help combat cervical cancer in developing nations
WHO awarded prequalification to Cervarix, cervical cancer vaccine, decision is for agencies to purchase the vaccine in developing countries
-
Alnylam joins GSK in donating intellectual property to patent pool for neglected tropical diseases
First company to join the pool since creation in March 2009
-
Landmark study for GSK’s cervical cancer vaccine published in The Lancet
Largest efficacy trial of a cervical cancer vaccine showed Cervarix® protects against the five most common cancer-causing virus types
-
GSK further extends its product portfolio in the Middle East and North Africa
GSK announced it's acquired the generics business of BMS in Lebanon, Jordan, Syria, Libya and Yemen for a cash consideration of $23.2m.
-
Seretide: Irish patent litigation update
GSK announced, Commercial Court in Dublin, Ireland, ruled in patent litigation regarding GSK8217, Seretide, treatment for asthma and COPD.
-
Regulatory update for REZONIC™ (casopitant mesylate)
GSK confirmed today that it has received a complete response letterfrom the FDA related to the application for casopitant
-
GSK and Chroma Therapeutics form alliance to develop novel macrophage-targeted drugs
GlaxoSmithKline (LSE: GSK) and Chroma Therapeutics Limited announced today a collaboration to develop macrophage-targeted compounds.
-
FDA extends review of Arzerra™ (ofatumumab)
GSK & Genmab announced, FDA informed the companies they have extended the action date for the ofatumumab BLA application by three months.
-
GSK announces a strategic alliance with Dr. Reddy’s to further accelerate sales growth in emerging markets
GSK announced an agreement with Dr. Reddy's to develop and market selected products across a number of emerging markets, excluding India.
-
GlaxoSmithKline update: A (H1N1) influenza
WHO raises influenza pandemic alert to phase 6
-
GSK and Shenzhen Neptunus create new alliance to develop and manufacture influenza vaccines in China
GSK announced it's entered into JV with Neptunus focused on developing and manufacturing influenza vaccines for the Chinese market.
-
Large, long-term study shows Avandia has no increased overall cardiovascular risk compared to other commonly used diabetes medicines
RECORD trial also demonstrates durable blood sugar control over time with Avandia
-
World Health Organization grants Global Prequalification to GSK’s Rotarix™ vaccine
Opens access to Asia and Africa – potential to save hundreds of thousands of lives
-
Positive results with Revolade™ and Arzerra™ for difficult-to-treat blood disorders
GSK announced data for Revolade & Arzerra at EHA meeting, results show potential of improvement in QoL in two haematological conditions.
-
GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs
GSK & Concert Pharmaceuticals to collaborate on deuterium-containing medicines, incl. CTP-518, a protease inhibitor for the treatment of HIV
-
GSK’s Pazopanib significantly delayed tumor progression in patients with advanced kidney cancer
GSK announced results of a Phase III study - pazopanib reduced the risk of tumor progression or death by 54 percent compared to placebo.1
-
FDA advisory panel makes favorable recommendation for ARZERRA (ofatumumab)
GSK & GEN announced that FDA voted 10:3 that ofatumumab, reasonably likely to predict clinical benefit for patients with chronic CLL.
-
US Department of Health and Human Services (HHS) purchases GSK’s A (H1N1) influenza antigen and proprietary adjuvant system
GSK announced HHS has placed initial orders for H1N1 vaccine antigen and proprietary adjuvant system, AS03.
-
GlaxoSmithKline update: A (H1N1) influenza vaccine development
GSK has received orders from several governments aiming to stockpile a H1N1 adjuvanted influenza vaccine as a precautionary measure.
-
GSK extends strategic collaboration with Aspen
GSK to acquire 16% shareholding in Aspen in exchange for transfer of specialist products and manufacturing facility in Bad Oldesloe, DE.